Previous Close | 17.08 |
Open | 17.08 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 17.08 - 17.08 |
52 Week Range | 15.55 - 22.55 |
Volume | |
Avg. Volume | 0 |
Market Cap | 1.349B |
Beta (5Y Monthly) | 0.44 |
PE Ratio (TTM) | 19.23 |
EPS (TTM) | 0.89 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 2 May 2022 – 7:00 PM CET Disclosure of received notification from NN Group N.V. Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from NN Group N.V. Notification from NN Group N.V. On 14 April 2022, Fagron received a notification that the shareholding of NN Group N.V. (NN Group) had crossed the disclosure threshold of 15% on 11 April 202
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 April 2022 – 7.00 AM CET Fagron reports 16% increase in revenue to € 156.4 million Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2022. Highlights Strong top line growth despite challenging operating environment Revenue increased by 16.0% to € 156.4 million (10.2% at constant exchange rates), with growth across all regions Organic growth o
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 8 April 2022 Fagron publishes agenda 2022 annual general meeting and extraordinary general meeting The Board of Directors of Fagron NV (Fagron) invites the holders of shares and subscription rights of Fagron to attend the annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 9 May 2022. Both meetings will be held in hybrid format. AgendaThe agenda includes the discussion of the a